

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### **Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

It was mentioned by Genetic Alliance UK and The Haemophilia Society (patient organisations) that although haemophilia is rare in females, they are often underserved and overlooked when being treated. There is a need to have effective products for this population as this may impact the need for hormonal therapy to control Heavy Menstrual Bleeding (HMB).

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

Stakeholders can submit evidence on differing, outcomes and quality of life between different populations. The committee can only appraise the technology within its marketing authorisation, but the scope does not exclude females. The committee will consider all potential equality issues during the appraisal process.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No change required as females are included in the wider population included in the scope.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
N/a

**Approved by Associate Director (name):** Ross Dent

**Date:** 24/02/2026